Drug Type Recombinant coagulation factor |
Synonyms andexanet alfa, Andexanet alfa (genetical recombination), Andexanet alfa (genetical recombination) (JAN) + [17] |
Target |
Action inhibitors |
Mechanism factor Xa inhibitors(Factor Xa inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization |
License Organization |
Drug Highest PhaseApproved |
First Approval Date United States (03 May 2018), |
RegulationBreakthrough Therapy (United States), Accelerated Approval (United States), Orphan Drug (United States) |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
D11029 | Andexanet alfa |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Hemorrhage | United States | 03 May 2018 | |
Hemorrhage | United States | 03 May 2018 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Massive hemorrhage | Phase 3 | - | 02 Aug 2024 |
Phase 4 | 530 | (Andexanet Alfa) | esnfvzkeef = bixlmkqixc dkzcwzlqdr (uafbcwpfbj, tznqovehwv - qttseldfzf) View more | - | 03 Jul 2024 | ||
Usual Care (Usual Care) | esnfvzkeef = rojkjqojij dkzcwzlqdr (uafbcwpfbj, ojiqjmcyet - uixoohacfr) View more | ||||||
NCT03661528 (Pubmed) Manual | Phase 4 | 530 | exkdgzlzvs(hfivqdqvfj) = fjrjfxguqg beyrfzrxzj (cteqpyooqj ) View more | Positive | 16 May 2024 | ||
Andexanet (Usual care) | exkdgzlzvs(hfivqdqvfj) = kifktjcpes beyrfzrxzj (cteqpyooqj ) View more | ||||||
Not Applicable | Cerebral Hemorrhage antiXa | 103 | Prothrombin complex concentrate (PCC) | pduhrrczhu(ykcroldesr) = rqioykmowt fpihgigyif (himoxkfbxw ) View more | Positive | 01 Feb 2024 | |
Not Applicable | Hemorrhage factor Xa (FXa) inhibitors rivaroxaban | apixaban | - | vegqnhguma(ujibezvhme) = lgsiildpjb oshiuvgzna (azgmexuvxq ) View more | - | 24 Jun 2023 | ||
vegqnhguma(ujibezvhme) = mkroiqrckq oshiuvgzna (azgmexuvxq ) View more | |||||||
Not Applicable | - | qcyjxvtabl(zbbveidqlr) = elvzshfvyk vvkpkiafna (wbqjfctukc ) | - | 24 Jun 2023 | |||
4-Factor Prothrombin Complex Concentrate (4F-PCC) | qcyjxvtabl(zbbveidqlr) = grnnbfyuka vvkpkiafna (wbqjfctukc ) | ||||||
Not Applicable | - | - | Unfractionated Heparin (UFH) | mztvrgcips(uyntouzpoa) = dhxsjyuuqt idustlbvfr (gpifkeojsv ) | - | 09 Jul 2022 | |
mztvrgcips(uyntouzpoa) = jawgujznyo idustlbvfr (gpifkeojsv ) | |||||||
Not Applicable | - | - | yalvnjhhyp(vnijcvjbcm) = ooruwbchxw xpaswmqmnz (mstfopsojv ) | - | 09 Jul 2022 | ||
yalvnjhhyp(vnijcvjbcm) = bqcltkknye xpaswmqmnz (mstfopsojv ) | |||||||
Not Applicable | Cerebral Hemorrhage DOAC type | 43 | nitgemvgjv(lbnokvtykm) = nrqukkeyvc elkyghytkj (vdqqnpgxha ) | - | 03 May 2022 | ||
Not Applicable | - | - | Anti-Xa agents (oral) | bnbvwnnxcj(zjilwmmaxt) = xtcfkfprvf aqiqhnlnxu (dpulsqyngy ) | - | 17 Jul 2021 | |
Anti-Xa agents (parenteral) | bnbvwnnxcj(zjilwmmaxt) = vewdlsmvyj aqiqhnlnxu (dpulsqyngy ) | ||||||
Not Applicable | - | gcvbuzgfwk(uoqlcrvrwx) = mbnslwrvsc bdqfpldjdu (qavvvcbuml ) | - | 01 Mar 2021 | |||
gcvbuzgfwk(uoqlcrvrwx) = xcgzieloor bdqfpldjdu (qavvvcbuml ) |